

## PRODUCT SPECIFICATION

### Anti-Complement component C5b-9 (human)

#### Mouse monoclonal antibody, biotinylated

Subclass: IgG2a/k

PRODUCT NO.

**DIA 011-01 B**

PRESENTATION

Preparation: Biotinylated  
 Content: 100 µL, 1 mg/mL  
 Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide  
 Storage: In the dark at 4-8°C

ANTIGEN

C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC (1,2).

IMMUNOGEN

Purified C5b-9

SPECIFICITY

DIA 011-01 binds both membrane-bound MAC and fluid-phase SC5b-9 complexes. DIA 011-01 cross-reacts with porcine (3), baboon (4) and equine TCC.

EPI TOPE SPECIFICITY

DIA 011-01 binds to a neoepitope exposed on C9

REACTIVITY

DIA 011-01 is well suited for quantifying TCC in ELISA and quantifying and characterizing TCC in various tissues by immunohistochemistry (frozen and paraffin sections). DIA 011-01 is not recommended for Western blotting as the epitope is destroyed during the process (1).

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

X63.Ag8.653

IMMUNIZATION

Female BALB/c mice immunized by intraperitoneal and subcutaneous injections

APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes	1/5000	
Immunoblotting	Not determined		
Immunohistochemistry	Not determined		

The dilution guideline for ELISA is based on sandwich ELISA in combination with a polyclonal antibody against the antigen. Users should determine the optimal dilutions for their own purpose.

REFERENCES

- Mollnes TE, Lea T, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. *Scand J Immunol* 22:183-195.
- Drogari-Aspiranthiou M, Kuijper EJ, Dekker N, Dankert J (2002) Complement activation and formation of the membrane attack complex on serogroup B *Neisseria meningitidis* in the presence or absence of serum bactericidal activity. *Infect Immunol* 70:3752-3758.
- Jansen JH, Högåsen K, Mollnes TE (1993) Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). *Am J Pathol* 143:1356-1365.
- Mollnes TE, Redl H, Högåsen K, Bengtsson A, Garred P, Speilberg L, Lea T, Oppermann M, Götze O, Schlag G (1993) Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). *Clin Exp Immunol* 91:295-300.
- Mollnes TE, Lea T, Froland SS, Harboe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. *Scand J Immunol* 22:197-202.
- Mollnes TE (1997) Analysis of in vivo complement activation. *Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C: Weir's Handbook of Experimental Immunology*. Boston, MA: Blackwell Science, pp. 78.1-78.8.
- Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P (1989) Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. *Gut* 30:361-6.
- Halstensen TS, Mollnes TE, Brandtzaeg P (1989) Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. *Gastroenterology* 97:10-9.
- Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P (1990) Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. *Gastroenterology* 98:1264-71.

#### CONDITIONS

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.

## PRODUCT SPECIFICATION

06/04/2010

**CONDITIONS**

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.

BioPorto Diagnostics A/S • Grusbakken 8 • DK-2820 Gentofte • Denmark • [info@bioporto.com](mailto:info@bioporto.com) • [www.bioporto.com](http://www.bioporto.com)  
Phone: +45 4529 0000 • Fax: +45 4529 0001 • CVR / Vat: DK-1864 5882